It is very uncertain whether duodenal stenting changes median survival postintervention compared with surgical palliation (very low certainty).
Duodenal stenting showed no clear difference in time to recurrence of obstructive symptoms compared with surgical palliation (moderate certainty).
It is very uncertain whether duodenal stenting changes adverse events compared with surgical palliation (very low certainty).
Duodenal stenting showed no clear difference in length of hospital stay compared with surgical palliation (moderate certainty).
The review found no eligible studies for this question.
The intervention showed no clear difference in death from all causes (low certainty).
It is very uncertain whether the intervention changes cancer (very low certainty).
It is very uncertain whether the intervention changes cancer (very low certainty).
It is very uncertain whether the intervention changes death from all causes (very low certainty).
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in overall survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (low certainty).
It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).